1. Home
  2. TMQ vs DSGN Comparison

TMQ vs DSGN Comparison

Compare TMQ & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trilogy Metals Inc.

TMQ

Trilogy Metals Inc.

HOLD

Current Price

$3.31

Market Cap

705.7M

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$13.84

Market Cap

819.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TMQ
DSGN
Founded
2004
2017
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
705.7M
819.6M
IPO Year
2012
2021

Fundamental Metrics

Financial Performance
Metric
TMQ
DSGN
Price
$3.31
$13.84
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$15.25
AVG Volume (30 Days)
2.3M
782.2K
Earning Date
04-02-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.30
$3.33
52 Week High
$11.29
$17.25

Technical Indicators

Market Signals
Indicator
TMQ
DSGN
Relative Strength Index (RSI) 32.91 67.46
Support Level $2.00 $9.78
Resistance Level $4.98 $17.10
Average True Range (ATR) 0.25 0.73
MACD -0.07 0.45
Stochastic Oscillator 1.08 82.96

Price Performance

Historical Comparison
TMQ
DSGN

About TMQ Trilogy Metals Inc.

Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the USA. Its properties include the Arctic copper-zinc-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: